Tenofovir gel, used vaginally before and after coitus, reduced women's acquisition of HIV by 39%. This is a safety assessment of tenofovir gel, including renal, bone, gastrointestinal, genital and haematological parameters.
Methods
In the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004, a double-blind, randomized placebo-controlled trial, 445 of the 889 eligibly enrolled women were assigned to tenofovir gel. All participants were advised to use the gel vaginally only, with one dose of gel within 12 h before and a second dose as soon as possible after sex, with no more than two doses in 24 h. Clinical and laboratory safety data were collected at monthly and quarterly visits, respectively. Genital assessments were undertaken at enrolment and quarterly thereafter, or as indicated.
Results
Women assigned to tenofovir gel were exposed to an average monthly vaginal dose of 240 mg of tenofovir (six applications). In total, six women, three in each group, had mild creatinine elevations, all of which occurred in July/ August 2008. The incidence of anaemia was 3.5 and 3.8 per 100 women-years in tenofovir and placebo groups, respectively (P=0.80). Of the six women (four tenofovir and two placebo) experiencing bone fractures, none were associated with abnormal phosphate or calcium values. The proportion of women with diarrhoea was higher in the tenofovir gel group (17% versus 11%; P=0.026). There was no significant increase of any genital adverse event in the tenofovir group.
Conclusions
No significant renal, haematological, genital or bone effects were associated with the use of tenofovir gel. Aside from a puzzling increase in diarrhoea, tenofovir gel has an excellent safety profile.
References
1.
UNAIDS.UNAIDS Report on the global AIDS Epidemic 2010. Geneva: Joint United Nations Programme on HIV/ AIDS. (Updated 11 February 2011. Accessed 11 February 2011.) Available from http://www.unaids.org/globalreport/.
2.
Abdool KarimQ., Abdool KarimS.S., FrohlichJ.A.Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science2010; 329: 1168–1174.
3.
WilliamsB.G., Abdool KarimS.S., Abdool KarimQ., GouwsE.Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J Acquir Immune Defic Syndr2011; 58: 207–210.
4.
Abdool KarimS.S., KashubaA., WernerL., Abdool KarimQ.Drug concentrations following topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet2011; 378: 279–281.
5.
Viread (tenofovir disoproxil fumarate).Package insert2008. Gilead Sciences, Inc., Foster City, CA, USA.
6.
NelsonM.R., KatlamaC., MontanerJ.The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS2007; 21: 1273–1281.
ParsonageM.J., WilkinsE.G., SnowdenN., IssaB.G., SavageM.W.The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med2005; 6: 341–346.
9.
GuptaS.K.Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS2008; 22: 99–103.
10.
CalmyA., FuxC.A., NorrisR.Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis2009; 200: 1746–1754.
11.
MulliganK., GliddenD., GonzalesP.Effects of FTC/ TDF on bone mineral density in seronegative men from 4 continents: DEXA results of the Global iPrEx Study.18th Conference of Retroviruses and Opportunistic Infections. 27 February–2 March 2011, Boston, MA, USA. Abstract 94LB.
12.
Gilead Sciences Inc. Investigators brochure: tenofovir gel (GS-1278)2010. Foster City, CA, USA: California Gilead Sciences, Inc.
13.
Abdool KarimQ., KharsanyA.B., NaidooK.Co-enrollment in multiple HIV prevention trials – experiences from the CAPRISA 004 Tenofovir gel trial. Contemp Clin Trials2011; 32: 333–338.
14.
MedDRA®.Medical Dictionary for Regulatory Activities. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). (Updated 1 March 2013. Accessed 27 March 2013.) Available from http://www.meddramsso.com/.
CockcroftD.W., GaultM.H.Prediction of creatinine clearance from serum creatinine. Nephron1976; 16: 31–41.
17.
MacQueenK., van LoggerenbergF., WeaverM.Behavioral recall accuracy in a microbicide trial: effects of psychological stress, serostatus, and timing of interview.M2010 Microbicides Conference: Building Bridges in HIV Prevention. 22–25 May 2010, Pittsburgh, PA, USA. Abstract 408.
18.
NuttallJ., KashubaA., WangR.The pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques in a microbicide trial.M2010 Microbicides Conference. 22–25 May 2010, Pittsburgh, PA, USA. Abstract 40.
19.
MayerK.H., MaslankowskiL., GaiF.Safety and tolerability of vaginal tenofovir gel in abstinent and sexually active HIV-infected and uninfected women. AIDS2006; 20: 543–551.
20.
GrantR.M., LamaJ.R., AndersonP.L.Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med2010; 363: 2587–2599.
21.
BaetenJ.M., DonnellD., NdaseP.Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. New Engl J Med2012; 367: 399–410.
22.
MarrazzoJ., RamjeeG., NairG.Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003).Conference on Retroviruses and Opportunistic Infections. 3–6 March 2013, Atlanta, GA, USA. Abstract 26LB.
